Growing Awareness of Skin Conditions Among Parents and Healthcare Providers and Product Approvals for Pediatrics has Propelled the Growth of the Pediatric dermatology treatment Market in the North America Region!
- Himanshu Patni
- August 12, 2023
- HEALTHCARE, NEWS
- Pediatric Dermatology Market, Pediatric Dermatology Market share, Pediatric Dermatology Market size, Pediatric Dermatology Marketgrowth, Pediatric Dermatology Markettrends
- 0 Comments
At present, the large number of children living in the region indicates a significant market opportunity for dermatology treatments for children. Moreover, growing awareness of skin conditions among parents and healthcare providers, increased investments in research and development for pediatric dermatology treatment coupled with technological advancements, and the rapid increase in the large pediatric population are propelling the growth of this market in the region. For example, according to the World Bank report, in 2022, the number of United States aged 0-14 has 18% of the total population.
Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=42583
Further, the North America Pediatric Dermatology Treatment Market is expected to grow at a strong CAGR of XX% during the forecast period (2022-2028) owing to the growing incidence of skin conditions such as atopic dermatitis, eczema, and acne are becoming more common in children in the region due to increased air pollution and changing lifestyles. The key players have rapidly adopted strategic alliances such as collaboration, product approval, and joint venture, to maintain a competitive edge in the global market. For instance, in June 2021, Novartis announced the U.S. Food and Drug Administration (FDA) approved Cosentyx for the treatment of moderate to severe plaque psoriasis in pediatric patients over the age of six who are candidates for systemic therapy or phototherapy1. This is the first approval for Cosentyx in a pediatric populace in the U.S.
Based on drug class, the market is segmented into anti-infectives, corticosteroids, anti-acne, calcineurin inhibitors, retinoids, and others. Amongst these, the anti-infectives segment dominated the market in 2021. This is because of the surge in awareness of the anti-infectives effectiveness in treating skin infections. The accessibility of anti-infective products also increases access to care for pediatric patients with skin infections. For instance, in February 2023, Pfizer’s supplemental New Drug Application for CIBINQO was approved by FDA, which provides the new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis.
For a detailed analysis of the Global Pediatric Dermatology Treatment Market browse through – https://univdatos.com/report/pediatric-dermatology-market/
By application, the market is segmented into alopecia, erythromelalgia, psoriasis, atopic dermatitis, and others. Among these, atopic dermatitis held a major share of the pediatric dermatology treatment market in 2021. The rising incidence of atopic dermatitis has created a rise in demand for pediatric dermatology products and services. For instance, in June 2022, FDA approved Dupixent (dupilumab) as the first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
Global Pediatric Dermatology Treatment Market Segmentation
Market Insight, by Drug Class
· Anti-Infectives
· Corticosteroids
· Anti-Acne
· Calcineurin Inhibitors
· Retinoids
· Others
Market Insights, by Application
· Alopecia
· Erythromelalgia
· Psoriasis
· Atopic Dermatitis
· Others
Market Insights, by End-Users
· Hospitals
· Clinics
· Cosmetic Centers
· Others
Market Insight, by Region
· North America
o U.S.
o Canada
o Rest of North America
· Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
· APAC
o China
o Japan
o India
o Rest of APAC
· Rest of the World
Top Company Profiles
· Novartis AG
· Amgen Inc.
· AbbVie Inc.
· Almirall S.A
· Bausch Health Companies Inc.
· Pfizer Inc.
· Johnson & Johnson Services, Inc.
· Merck & Co., Inc.
· Sanofi S.A.
· Bristol Myers Squibb Company
Related Posts
